Visceral Steatosis, Congenital disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: VSC053 MIFTS: 34	Visceral Steatosis, Congenital Categories: Liver diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Visceral Steatosis, Congenital

MalaCards integrated aliases for Visceral Steatosis, Congenital:

Name: Visceral Steatosis, Congenital ⁵⁷

Fatty Metamorphosis of Viscera ⁵⁷ ⁷¹

Fatty Liver Disease, Congenital ⁵⁷

White Liver Disease ⁵⁷

Steatosis of Liver ⁵⁷

Liver Steatosis ⁶

Characteristics:

OMIM®:

⁵⁷ (Updated 05-Mar-2021)

Inheritance:
autosomal recessive

HPO:

³¹

visceral steatosis, congenital:
Onset and clinical course neonatal death
Inheritance autosomal recessive inheritance

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Liver diseases

See all MalaCards categories (disease lists)

External Ids:

OMIM® ⁵⁷ 228100

MedGen ⁴¹ C0341447

UMLS ⁷¹ C0341447

Sources

Summaries for Visceral Steatosis, Congenital

MalaCards based summary : Visceral Steatosis, Congenital, also known as fatty metamorphosis of viscera, is related to visceral steatosis and fatty liver disease. An important gene associated with Visceral Steatosis, Congenital is PRMT7 (Protein Arginine Methyltransferase 7). The drugs Amlodipine and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and skeletal muscle, and related phenotypes are hypoglycemia and hepatic steatosis

More information from OMIM: 228100

Sources

Related Diseases for Visceral Steatosis, Congenital

Diseases in the Visceral Steatosis family:

Visceral Steatosis, Congenital

Diseases related to Visceral Steatosis, Congenital via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 165)

#	Related Disease	Score
1	visceral steatosis	11.6
2	fatty liver disease	11.2
3	lipodystrophy, familial partial, type 2	11.0
4	pearson marrow-pancreas syndrome	11.0
5	combined oxidative phosphorylation deficiency 16	11.0
6	infantile liver failure syndrome 1	11.0
7	infantile liver failure syndrome 2	11.0
8	congenital generalized lipodystrophy	11.0
9	fatty liver disease, nonalcoholic 1	11.0
10	non-alcoholic steatohepatitis	10.7
11	hepatitis c	10.6
12	lipid metabolism disorder	10.5
13	hepatitis c virus	10.5
14	body mass index quantitative trait locus 11	10.5
15	body mass index quantitative trait locus 9	10.5
16	body mass index quantitative trait locus 8	10.5
17	body mass index quantitative trait locus 4	10.5
18	body mass index quantitative trait locus 10	10.5
19	body mass index quantitative trait locus 7	10.5
20	body mass index quantitative trait locus 12	10.5
21	body mass index quantitative trait locus 14	10.5
22	body mass index quantitative trait locus 18	10.5
23	body mass index quantitative trait locus 19	10.5
24	liver disease	10.5
25	hepatitis b	10.5
26	hepatitis	10.5
27	hypertriglyceridemia, familial	10.5
28	body mass index quantitative trait locus 1	10.4
29	hemosiderosis	10.4
30	rare hereditary hemochromatosis	10.4
31	viral hepatitis	10.3
32	leptin deficiency or dysfunction	10.3
33	glucose intolerance	10.3
34	hyperglycemia	10.3
35	type 2 diabetes mellitus	10.3
36	hypercholesterolemia, familial, 1	10.3
37	rapidly involuting congenital hemangioma	10.2
38	non-alcoholic fatty liver disease	10.2
39	hyperinsulinism	10.2
40	liver cirrhosis	10.2
41	atherosclerosis susceptibility	10.1
42	hepatocellular carcinoma	10.1
43	inflammatory bowel disease	10.1
44	diabetes mellitus	10.1
45	48,xyyy	10.1
46	immune deficiency disease	10.1
47	cholestasis	10.1
48	alcohol use disorder	10.1
49	severe acute respiratory syndrome	10.1
50	ischemia	10.1

Graphical network of the top 20 diseases related to Visceral Steatosis, Congenital:

Sources

Symptoms & Phenotypes for Visceral Steatosis, Congenital

Human phenotypes related to Visceral Steatosis, Congenital:

³¹ (show all 14)

#	Description	HPO Source Accession
1	hypoglycemia ³¹	HP:0001943
2	hepatic steatosis ³¹	HP:0001397
3	jaundice ³¹	HP:0000952
4	hypocalcemia ³¹	HP:0002901
5	abnormal bleeding ³¹	HP:0001892
6	lethargy ³¹	HP:0001254
7	coma ³¹	HP:0001259
8	abnormality of the genitourinary system ³¹	HP:0000119
9	generalized hypotonia ³¹	HP:0001290
10	kernicterus ³¹	HP:0001343
11	renal steatosis ³¹	HP:0000799
12	myocardial steatosis ³¹	HP:0006693
13	seizure ³¹	HP:0001250
14	hypotonia ³¹	HP:0001252

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 05-Mar-2021)

Neuro:
seizures
lethargy
coma
kernicterus
hypotonia

G I:
jaundice
hepatosteatosis

G U:
renal steatosis

Heme:
hemorrhagic disorder

Lab:
hypoglycemia
hypocalcemia
elevated tissue fatty acids and triglycerides

Misc:
neonatal death

Cardiac:
myocardial steatosis

Clinical features from OMIM®:

228100 (Updated 05-Mar-2021)

Sources

Drugs & Therapeutics for Visceral Steatosis, Congenital

Drugs for Visceral Steatosis, Congenital (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Amlodipine

Approved

Phase 4

88150-42-9

2162

Synonyms:

()-Amlodipine

(RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate

2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)

-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyridine

3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester

3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester

3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate

3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate

3-Ethyl 5-methylester, (±)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate

3-Ethyl-5-methyl ( -)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat

3-Ethyl-5-methyl ( -)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate

3-Ethyl-5-methyl (.+/-.)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate

3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate

3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(O-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate

3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(O-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid

3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate

88150-42-9

88150-47-4 (maleate (1:1))

AC1L1D26

AC1Q32ZS

AC-4535

Almirall brand OF amlodipine besilate

Ambap88150-42-9

Amlocard

amlodipine

Amlodipine

Amlodipine (INN)

Amlodipine [INN:BAN]

AMLODIPINE BASE

Amlodipine Benzenesulfonate

Amlodipine besilate

Amlodipine Besilate

Amlodipine besylate

Amlodipine Besylate

Amlodipine free base

Amlodipine Free Base

Amlodipine maleate

Amlodipine maleate (1:1)

Amlodipine, (+-)-isomer

Amlodipine, (+-)-isomer, maleate (1:1)

Amlodipine, (R)-isomer

Amlodipine, (S)-isomer, maleate (1:1)

Amlodipino

Amlodipino [Spanish]

Amlodipinum

Amlodipinum [Latin]

Amlodis

Amlopres

Amlor

Amvaz

AMVAZ

Astudal

BIDD:GT0810

BRD-A22032524-074-02-4

BRD-A22032524-074-03-2

BSPBio_002727

C06825

CHEBI:2668

CHEMBL1491

CID2162

Coroval

CPD000469198

D07450

DB00381

Eczacibasi brand OF amlodipine besilate

HMS2052N03

HMS2089H07

I14-0798

Intervask

Istin

KBio3_001947

KBioGR_001643

Lipinox

Lotrel

LS-131183

Mack brand OF amlodipine besilate

MLS001401409

MolPort-001-792-963

NCGC00165957-01

NCGC00165957-02

NCGC00165957-03

Norvasc

Norvasc (TN)

Pelmec

Pfizer brand OF amlodipine besilate

R,S)-Amlodipine

Racemic amlodipine

Racemic Amlodipine

SAM001246705

SMR000469198

SPBio_000351

Spectrum2_000486

Spectrum3_001004

Spectrum4_001132

Spectrum5_001550

UK-4834011

UNII-1J444QC288

Angiotensin II

Approved, Investigational

Phase 4

68521-88-0, 4474-91-3, 11128-99-7

172198

Synonyms:

1-8-Angiotensin I

1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide

5 L Isoleucine angiotensin II

5-isoleucine-angiotensin II

5-Isoleucine-angiotensin II

5-L-Isoleucine angiotensin II

5-L-isoleucineangiotensin II

5-L-Isoleucineangiotensin II

Ang II

ANG-(1-8)octapeptide

Angiotensin

Angiotensin 2

Angiotensin II

Angiotensin II (human)

Angiotensin II (mouse)

Angiotensin II, 5-L-isoleucine

Angiotensin-(1-8) octapeptide

Angiotonin

Asp-arg-val-tyr-ile-his-pro-phe

Delivert

Human angiotensin II

Hypertensin

II, 5-L-isoleucine angiotensin

Ile(5)-angiotensin II

Ile5-angiotensin II

Isoleucine(5)-angiotensin

Isoleucine(5)-angiotensin II

isoleucine5-angiotensin II

Isoleucyl(5)-angiotensin II

N-(1-(N-(N-(N-(N-(N(2)-L-a-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine

N-(1-(N-(N-(N-(N-(N(2)-L-alpha-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine

N-(1-(N-(N-(N-(N-(N(2)-L-Α-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine

Valyl(5)-angiotensin II

Simvastatin

Approved

Phase 4

79902-63-9

54454

Synonyms:

(+)-Simvastatin

(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate

[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate

2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester

2,2-Dimethylbutyrate, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one

2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one

2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one

2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one

79902-63-9

AC-1530

AC1L1H1F

AKOS005111006

ARONIS24119

BCBcMAP01_000007

BIDD:GT0769

Bio-0672

BPBio1_001001

BRD-K22134346-001-05-8

BRN 4768037

BSPBio_000909

BSPBio_002337

Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester

Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester

Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester

butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta

C25H38O5

CCRIS 7558

CHEBI:9150

CHEMBL1064

Cholestat

CID54454

Coledis

Colemin

Corolin

CPD000718785

D00434

D019821

Denan

DivK1c_006991

DRG-0320

Eucor

HMS1570N11

HMS1922H13

HMS2089D12

HMS2093E06

HSDB 7208

InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1

KBio1_001935

KBio2_002197

KBio2_004765

KBio2_007333

KBio3_001557

KBioGR_001244

KBioSS_002197

Kolestevan

KS-1113

L 644128-000U

Labistatin

Lipex

Lipinorm

Liponorm

Lipovas

Lodales

LS-46264

Medipo

MK 0733

MK 733

MK-0733

MK733

MK-733

MLS001304029

MLS001333077

MLS001333078

MLS002154038

Modutrol

MolPort-002-507-345

MolPort-002-885-862

NCGC00017324-01

NCGC00017324-02

NCGC00017324-03

nchembio790-comp16

Nivelipol

Nor-vastina

Pantok

Pepstatin

Prestwick_171

Prestwick0_000865

Prestwick1_000865

Prestwick2_000865

Prestwick3_000865

Rechol

Rendapid

S1792_Selleck

S6196_SIGMA

SAM002589969

Simcor

Simovil

Simvast CR

simvastatin

Simvastatin

Simvastatin & Primycin

Simvastatin (JAN/USP/INN)

Simvastatin [Usan:Ban:Inn]

Simvastatin [USAN:INN:BAN]

Simvastatin lactone

Simvastatin, Compactin

Simvastatina

Simvastatina [Spanish]

Simvastatine

Simvastatine [French]

Simvastatinum

Simvastatinum [Latin]

Simvotin

Sinvacor

Sinvascor

Sivastin

SMR000718785

SPBio_001881

SPBio_002830

SpecPlus_000895

Spectrum_001717

SPECTRUM1504236

Spectrum2_001671

Spectrum3_000669

Spectrum4_000632

Spectrum5_001428

Statin

STK801938

Synvinolin

TNP00259

UNII-AGG2FN16EV

Valemia

Vasotenal

Velostatin

Vytorin

ZINC03780893

Zocor

Zocor (TN)

Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin

Zocord

Losartan

Approved

Phase 4

114798-26-4

3961

Synonyms:

(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol

(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol

(2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol

[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol

114798-26-4

124750-99-8 (mono-potassium salt)

1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)

2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol

2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-1H-imidazole-5-methanol

2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5ylphenyl)benzyl]imidazole-5-methanol

2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole

2-N-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole

2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]methyl]imidazole

AC1L1H3Q

BIDD:GT0286

BRD-K76205745-001-02-5

BSPBio_002695

C07072

C22H23ClN6O

CHEBI:6541

CHEMBL191

CID3961

CL23623

Cozaar

D08146

DB00678

DuP 753

DUP 89

DuP-753

HMS1922J13

HMS2093E22

Hyzaar

I14-9710

Jsp001094

KBio2_002193

KBio2_004761

KBio2_007329

KBio3_001915

KBioGR_001611

KBioSS_002193

L000351

Lortaan

losartan

Losartan

Losartan (INN)

Losartan [INN:BAN]

Losartan monopotassium salt

losartan potassium

Losartan potassium

LOSARTAN POTASSIUM

Losartic

Losartic (TN)

LS-78746

MK954

MK-954

MolPort-003-666-553

Monopotassium salt, losartan

NCGC00095125-01

NCGC00095125-02

NCGC00095125-03

Oprea1_644635

Potassium, losartan

Salt, losartan monopotassium

SPBio_001893

Spectrum_001713

SPECTRUM1504268

Spectrum2_001677

Spectrum3_000998

Spectrum4_001126

Spectrum5_001466

UNII-JMS50MPO89

Efavirenz

Approved, Investigational

Phase 4

154598-52-4

64139

Synonyms:

(-)-6-CHLORO-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one

(-)-Efavirenz

(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one

(4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one

(4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one

(4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one

(S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben

(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-(S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one

(S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one

(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one

(S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one

(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one

(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[D][1,3]oxazin-2-one

154598-52-4

1ikv

1ikw

2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)- (9

6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one

6-Chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[D][1,3]oxazin-2-one

AC-19049

AC1L20IX

BIDD:GT0383

Bristol-myers squibb brand OF efavirenz

C08088

C14H9ClF3NO2

CHEBI:119486

CHEMBL223228

CID64139

CPD000466351

D00896

DB00625

DB07709

DMP 266

DMP-266

Du pont brand OF efavirenz

efavirenz

Efavirenz

Éfavirenz

Efavirenz (JAN/INN)

Efavirenz, (R)-isomer

efavirenz, (S)-isomer

Efavirenz, (S)-isomer

Efavirenzum

EFV

EFZ

Eravirenz

HMS2051J08

HMS2090N16

HSDB 7163

L 743726

L-741211

L-743,726

L-743725

L-743726

LS-173464

Merck sharp and dohme brand OF efavirenz

Met-SDF-1.beta. & Efavirenz

Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz

MLS000759465

MLS001424087

MolPort-003-983-924

NSC742403

SAM001246667

SBB066062

SMR000466351

Stocrin

Strocin (TM)

Sustiva

Sustiva (TM)

Sustiva (TN)

UNII-JE6H2O27P8

United drug brand OF efavirenz

ZINC02020233

zoxazin-2-one

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Phase 4

Hypolipidemic Agents

Phase 4

Antimetabolites

Phase 4

Lipid Regulating Agents

Phase 4

Anticholesteremic Agents

Phase 4

Hormones

Phase 4

Anti-Arrhythmia Agents

Phase 4

Angiotensinogen

Phase 4

Antihypertensive Agents

Phase 4

Giapreza

Phase 4

Angiotensin II Type 1 Receptor Blockers

Phase 4

Calcium, Dietary

Phase 4

Angiotensin Receptor Antagonists

Phase 4

calcium channel blockers

Phase 4

Vasodilator Agents

Phase 4

Cytochrome P-450 Enzyme Inhibitors

Phase 4

Anti-HIV Agents

Phase 4

Raltegravir Potassium

Phase 4

Anti-Infective Agents

Phase 4

Reverse Transcriptase Inhibitors

Phase 4

Antiviral Agents

Phase 4

HIV Integrase Inhibitors

Phase 4

Anti-Retroviral Agents

Phase 4

Integrase Inhibitors

Phase 4

Calcium

Nutraceutical

Phase 4

7440-70-2

271

Synonyms:

Ca(2+)

Ca2+

Calcio

Calcium

Calcium element

CALCIUM ion

Calcium(2+)

Calcium, doubly charged positive ion

Calcium, elemental

Elemental calcium

Kalzium

Metformin

Approved

657-24-9

14219 4091

Synonyms:

1,1-Dimethyl biguanide

1,1-Dimethylbiguanide

3-(diaminomethylidene)-1,1-dimethylguanidine

657-24-9

AC1L1HE4

AKOS000121065

Apo-Metformin

BIDD:GT0697

BPBio1_000009

BRD-K79602928-003-04-1

BSPBio_000007

BSPBio_002314

C07151

C4H11N5

CAS-1115-70-4

CCRIS 9321

CHEBI:6801

CHEMBL1431

CID4091

cMAP_000016

D04966

DB00331

Diabetosan

Diabex

Dimethylbiguanid

Dimethylbiguanide

Dimethylbiguanidine

Dimethyldiguanide

Dimethylguanylguanidine

DMGG

EINECS 211-517-8

Fluamine

Flumamine

Fortamet

Gen-Metformin

Glifage

Gliguanid

Glucophage

Glucophage XR

Glumetza

Glycon

Haurymelin

HMS2089D19

HSCI1_000295

Islotin

KBio2_002310

KBio2_004878

KBio2_007446

KBio3_002790

KBioGR_002310

KBioSS_002312

LA-6023

LS-43899

Melbin

metformin

Metformin

Metformin (USAN/INN)

Metformin [USAN:INN:BAN]

Metformin HCL

metformin hydrochloride

Metformina

Metformina [DCIT]

Metformina [Spanish]

Metformine

Metformine [INN-French]

Metforminum

Metforminum [INN-Latin]

Metiguanide

MolPort-002-929-560

MolPort-004-288-389

MolPort-005-767-418

Mylan-Metformin

N,N-Dimethylbiguanide

N,N-Dimethyldiguanide

N,N-dimethylimidodicarbonimidic diamide

N1,N1-Dimethylbiguanide

NCGC00016564-01

NCGC00016564-02

NCGC00016564-03

NNDG

Novo-Metformin

Nu-Metformin

PMS-Metformin

Prestwick0_000004

Prestwick1_000004

Prestwick2_000004

Prestwick3_000004

Ran-Metformin

Ratio-Metformin

Riomet

S2483_Selleck

Sandoz Metformin

Siofor

SPBio_001928

STK011633

T5895664

Teva-Metformin

UNII-9100L32L2N

ZINC12859773

Omega 3 Fatty Acid

Antioxidants

Complement C3

carnitine

Insulin, Globin Zinc

insulin

Liver Extracts

Arginine

Investigational, Nutraceutical

74-79-3

6322

Synonyms:

(2S)-2-Amino-5-(carbamimidamido)pentanoate

(2S)-2-amino-5-(carbamimidamido)pentanoic acid

(2S)-2-Amino-5-(carbamimidamido)pentanoic acid

(2S)-2-Amino-5-guanidinopentanoate

(2S)-2-amino-5-guanidinopentanoic acid

(2S)-2-Amino-5-guanidinopentanoic acid

(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoate

(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoate

(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid

(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoic acid

(S)-2-Amino-5-guanidinopentanoate

(S)-2-amino-5-guanidinopentanoic acid

(S)-2-Amino-5-guanidinopentanoic acid

(S)-2-Amino-5-guanidinovalerate

(S)-2-Amino-5-guanidinovaleric acid

2-Amino-5-guanidinovalerate

2-Amino-5-guanidinovaleric acid

5-[(Aminoiminomethyl)amino]-L-norvaline

Arg

Arginina

Arginine

Arginine hydrochloride

Arginine, L isomer

Arginine, L-isomer

DL Arginine acetate, monohydrate

DL-Arginine acetate, monohydrate

Hydrochloride, arginine

L Arginine

L-(+)-Arginine

L-a-Amino-D-guanidinovalerate

L-a-Amino-D-guanidinovaleric acid

L-alpha-Amino-delta-guanidinovalerate

L-alpha-Amino-delta-guanidinovaleric acid

L-Arg

L-Arginin

L-arginine

L-Isomer arginine

Monohydrate DL-arginine acetate

N5-(Aminoiminomethyl)-L-ornithine

Interventional clinical trials:

(show all 25)

#	Name	Status	NCT ID	Phase	Drugs
1	Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients	Unknown status	NCT00669435	Phase 4	Losartan + Simvastatin;Amlodipine + Simvastatin
2	Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among HIV/HCV-Coinfected Patients Receiving Two Nucleoside Analogs Plus Efavirenz: The Steral Study	Completed	NCT01900015	Phase 4	Raltegravir;Efavirenz
3	Non-invasive Assessment of Liver Steatosis and Stiffness in HIV-infected Patients With Controlled Attenuation Parameter and Transient Elastography	Unknown status	NCT03599882
4	Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver Fibrosis	Unknown status	NCT03386890
5	Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis	Unknown status	NCT02575625
6	Hepaxa Management of Non-Alcoholic Fatty Liver Disease (NAFLD): A Real-world Pilot Study Observing Effects of Nutritional Management With Hepaxa in Subjects With Liver Steatosis	Unknown status	NCT03801577
7	Growth Hormone Replacement in Adults With Growth Hormone Deficiency (GHD) - The Effect on Liver Fat.	Completed	NCT00774579
8	Multi Center Survey on Spine and Hip Status in Chinese Population Using Quantitative Computed Tomography (QCT)	Completed	NCT01758770
9	Usefulness of Controlled Attenuation Parameter (CAP) for the Assessment of Liver Steatosis in Liver Donors	Completed	NCT02798861
10	Hepatitis C Infection With Liver Steatosis Compared to Hepatitis C Infection Without Liver Steatosis: Is There a Difference in Lipid Peroxidation and Indicators of Inflammation?	Completed	NCT00444002
11	Effects of Fructose Restriction on Liver Steatosis	Completed	NCT03067428
12	Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons	Completed	NCT00889577
13	The Influence of Apolipoprotein C3 Variants on Liver Steatosis and Serum Liver Enzyme Values in Obese Children	Completed	NCT01682655
14	Effect of Low-glycemic Index Lunches and Dinners Intake on Indicators of Satiety, Metabolic Parameters and Liver Steatosis Degree on Women With Type 2 Diabetes Under Metformin Therapy: Controlled Clinical Trial	Completed	NCT03165877
15	Influence of Bariatric Endoscopy on Clinical Course of NAFLD	Recruiting	NCT04669470
16	Non-invasive Evaluation of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease by Assessment of Spleen Stiffness Using Vibration Controlled Transient Elastography	Recruiting	NCT03778411
17	Screening With FibroTouch for Advanced Liver Fibrosis in NAFLD Patients With Underlying Type 2 Diabetes：A Registry and Diagnostic Cohort Study	Recruiting	NCT03525769
18	Non-Invasive Evaluation of Liver Steatosis, Inflammation and Fibrosis	Recruiting	NCT02754037
19	The Prevalence of Liver Steatosis, Steatohepatitis, Fibrosis, and Hemosiderosis in Overweight and Obese US Military Dependent Pediatric Patients Using MR Elastography and Quantitative MRI	Recruiting	NCT04284371
20	Study for the Identification of Participants With Liver Steatosis Who Carry Genetic Variants Associated With Nonalcoholic Fatty Liver Disease (NAFLD)	Recruiting	NCT04494360
21	Effect of Carnitine Supplementation on Liver Steatosis, Insulin Sensitivity, Plasma Glucose Homeostasis, Skeletal Muscle Metabolism and Energetics: a Pilot Study	Active, not recruiting	NCT03439917
22	The Liver in the World Trade Center Health Program General Responder Cohort and Controls	Enrolling by invitation	NCT03858920
23	Effects of Nutritional Supplementation With Amino Acids on Liver Lipid Content, Whole-body Protein Turnover, and Body Composition in Obese Pre-pubertal Children	Not yet recruiting	NCT02337894
24	Impact of the Hepatitis C Virus Variability on Liver Steatosis	Terminated	NCT00843076
25	Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment	Withdrawn	NCT01987310		atorvastatin

Search NIH Clinical Center for Visceral Steatosis, Congenital

Sources

Genetic Tests for Visceral Steatosis, Congenital

Sources

Anatomical Context for Visceral Steatosis, Congenital

MalaCards organs/tissues related to Visceral Steatosis, Congenital:

⁴⁰

Liver, Spleen, Skeletal Muscle, Endothelial, Kidney

Sources

Publications for Visceral Steatosis, Congenital

Articles related to Visceral Steatosis, Congenital:

(show all 36)

#	Title	Authors	PMID	Year
1	"WHITE LIVER" DISEASE. ⁵⁷ ⁶¹	UTIAN HL...SICHEL RJ	14206017	1964
2	Neonatal hepatic steatosis by disruption of the adenosine kinase gene. ⁵⁷	Boison D...Mohler H	11997462	2002
3	Nonketotic C6-C10-dicarboxylic aciduria presenting as familial hepatic steatosis. ⁵⁷	Simila S...Gregerson N	6476011	1984
4	A three-month-old infant with seizures, hypoglycemia, and apnea. ⁵⁷	Chesney RW...Odell GB	6650573	1983
5	Fatal familial steatosis of myocardium, liver and kidneys in three siblings. ⁵⁷	Suprun H...Freundlich E	7234407	1981
6	Familial disease characterized by neonatal jaundice, and probable hepatosteatosis and kernicterus: a new syndrome? ⁵⁷	Wadlington WB...Riley HD	4695852	1973
7	Fatal familial steatosis of the liver and kidney in two siblings. ⁵⁷	Rasanen O...Hakosalo J	5567005	1971
8	Fatal neonatal heptic steatosis: a new familial disorder. ⁵⁷	Satran L...Krivit W	5790404	1969
9	Familial metabolic disorder with fatty metamorphosis of the viscera. ⁵⁷	Peremans J...De Block G	5953838	1966
10	ENCEPHALOPATHY AND FATTY DEGENERATION OF THE VISCERA. A DISEASE ENTITY IN CHILDHOOD. ⁵⁷	REYE RD...BARAL J	14055046	1963
11	Keratin variants predispose to acute liver failure and adverse outcome: race and ethnic associations. ⁶¹	Strnad P...Omary MB	20538000	2010
12	Hepatic encephalopathy associated with cobalt deficiency and white liver disease in lambs. ⁶¹	Sargison ND...Rhind SM	11808665	2001
13	Hepatic lipidosis associated with cobalt deficiency in Omani goats. ⁶¹	Johnson EH...Hameed MS	10461798	1999
14	[Occurrence of white liver dis in lambs in Switzerland]. ⁶¹	Tontis A...Meier W	9626744	1998
15	Histopathologic and ultrastructural alterations of white liver disease in sheep experimentally depleted of cobalt. ⁶¹	Kennedy S...Blanchflower WJ	9396138	1997
16	An outbreak of ovine white liver disease in south west England. ⁶¹	Dannatt L...Porter TA	8903021	1996
17	Cobalt-vitamin B12 deficiency causes lipid accumulation, lipid peroxidation and decreased alpha-tocopherol concentrations in the liver of sheep. ⁶¹	Kennedy DG...Kennedy S	7883464	1994
18	Cobalt deficiency in pastured sheep in the south-western Cape Province. ⁶¹	Schneider DJ...Green JR	1941894	1991
19	[Cobalt deficiency and photosensitivity in a flock of Texel lambs]. ⁶¹	Hesselink JW...Vellema P	2219077	1990
20	Ovine white-liver disease (OWLD) in Norway: clinical symptoms and preventive measures. ⁶¹	Ulvund MJ...Pestalozzi M	2399872	1990
21	Ovine white-liver disease (OWLD). Serum copper and effects of copper and selenium supplementation. ⁶¹	Ulvund MJ	2080773	1990
22	Ovine white-liver disease (OWLD). Treatment trials. ⁶¹	Ulvund MJ	2080781	1990
23	The possible significance of fructan in pasture grass for the development of ovine white-liver disease (OWLD). ⁶¹	Ulvund MJ...Pestalozzi M	2080782	1990
24	Ovine white-liver disease (OWLD). Botanical and chemical composition of pasture grass. ⁶¹	Ulvund MJ...Pestalozzi M	2080770	1990
25	Ovine white-liver disease (OWLD). Pathology. ⁶¹	Ulvund MJ	2080775	1990
26	Ovine white-liver disease (OWLD). Trace elements in liver. ⁶¹	Ulvund MJ	2080774	1990
27	Ovine white-liver disease (OWLD). Vitamin B12 and methyl malonic acid (MMA) estimations in blood. ⁶¹	Ulvund MJ	2080771	1990
28	Ovine white-liver disease (OWLD). Changes in blood chemistry. ⁶¹	Ulvund MJ	2080772	1990
29	White liver disease in goats. ⁶¹	Black H...James MP	16031425	1988
30	Liver lesions resembling ovine white liver disease in cobalt deficient lambs. ⁶¹	McLoughlin MF...Taylor SM	6495593	1984
31	Ovine white liver disease. ⁶¹	Mason RW...McKay R	6639520	1983
32	White liver disease of sheep. ⁶¹	Mitchell PJ...McCausland IP	7138431	1982
33	White liver disease in lambs. ⁶¹	Richards RB...Harrison MR	7340780	1981
34	Ovine white liver disease--an hepatic dysfunction associated with vitamin B12 deficiency. ⁶¹	Sutherland RJ...Carthew GC	294529	1979
35	A condition resembling ovine white liver disease in lambs on irrigated pasture in South Canterbury. ⁶¹	Clark RG...Jones BA	284244	1978
36	"WHITE LIVER" DISEASE. ⁶¹	TAN KY	14317663	1965

Sources

Genes for Visceral Steatosis, Congenital

Genes related to Visceral Steatosis, Congenital (1 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	PRMT7	Protein Arginine Methyltransferase 7	Protein Coding	400	Pathogenic ⁶

Sources

Variations for Visceral Steatosis, Congenital

ClinVar genetic disease variations for Visceral Steatosis, Congenital:

⁶

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	GRCh37 Pos	GRCh38 Pos
1	PRMT7	NM_019023.5(PRMT7):c.322G>T (p.Glu108Ter)	SNV	Pathogenic	523435	rs1014959895	16:68363008-68363008	16:68329105-68329105
2	PRMT7	NM_019023.5(PRMT7):c.1713C>A (p.Cys571Ter)	SNV	Pathogenic	523434	rs1251713297	16:68389688-68389688	16:68355785-68355785
3	MT-TL1	NC_012920.1:m.3275C>T	SNV	Uncertain significance	370045	rs1057516057	MT:3275-3275	MT:3275-3275
4	OPA1	NM_001354663.2(OPA1):c.-260_-243del	Deletion	Uncertain significance	214916	rs863224140	3:193332587-193332604	3:193614798-193614815

Sources

Expression for Visceral Steatosis, Congenital

Search GEO for disease gene expression data for Visceral Steatosis, Congenital.

Sources

Pathways for Visceral Steatosis, Congenital

Sources

GO Terms for Visceral Steatosis, Congenital

Sources

Sources for Visceral Steatosis, Congenital

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Mar-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia